

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7054728

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JOHN H. BAILLIE	10/03/2017
RUTH BAILLIE	10/05/2017
GEORGE BLOUIN	10/03/2017
NEWSHA FARAHANI	10/03/2017
CHRISTOPHER MARX	10/03/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GESEA BIOSCIENCES, INC.
<b>Street Address:</b>	6895 AVILA VALLEY DRIVE
<b>City:</b>	SAN LUIS OBISPO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	93405
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17531658
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6504463320
<b>Email:</b>	patents@vlpawgroup.com
<b>Correspondent Name:</b>	VLP LAW GROUP, LLP
<b>Address Line 1:</b>	555 BRYANT STREET SUITE 820
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94301
<b>ATTORNEY DOCKET NUMBER:</b>	2434-02-001U04
<b>NAME OF SUBMITTER:</b>	ANGELA WENDEL
<b>SIGNATURE:</b>	/angela wendel/
<b>DATE SIGNED:</b>	12/03/2021
<b>Total Attachments: 4</b>	
source=20211203_2434-02-001U04_TPO_Parent_Assignment_signed#page1.tif	

source=20211203\_2434-02-001U04\_TPO\_Parent\_Assignment\_signed#page2.tif

source=20211203\_2434-02-001U04\_TPO\_Parent\_Assignment\_signed#page3.tif

source=20211203\_2434-02-001U04\_TPO\_Parent\_Assignment\_signed#page4.tif

## **ASSIGNMENT OF RIGHTS IN INVENTION(S)**

For valuable consideration, We:

John H. Baillie, Ruth Baillie, George Blouin, Newsha Farahani, and Christopher Marx (the "ASSIGNORS") hereby assign to Gesea Biosciences, Inc., a company organized under the laws of California and having an address of 15022 35th Avenue West, Suite F, Lynwood, Washington 98087, and its successors, assigns, and legal representatives (collectively hereinafter the "ASSIGNEE"),

the entire right, title and interest throughout the world in the invention(s) which is/are disclosed and claimed in an application for patent in the United States of America, executed by us, entitled "BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE," filed on September 29, 2017 and having Application Serial No. 15/720,921, this assignment including:

said United States patent application, and any and all United States and foreign patents, utility models, and design registrations which may be applied for and granted for any of said invention(s) and improvement(s) thereof, and in and to any and all divisions, continuations, continuations-in-part, reissues, certificates of re-examination, supplemental protection certificates, patent term restorations, and patents of addition, in any country, that may be based thereon;

the right of ASSIGNEE to claim priority based on the filing date of said application in the United States of America, under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, including without limitation all rights in an international application claiming benefit of priority to said United States patent application, and all rights, privileges and advantages appertaining thereto, including any and all provisional rights;

the right of ASSIGNEE to enforce and to license, and to collect damages, profits or recoveries of any nature for past or future infringement of, any United States or foreign patent(s) that may be granted thereon;

the right of ASSIGNEE to prosecute, with the assistance of competent counsel, any of the foregoing patent applications in any jurisdiction worldwide; and

the right of ASSIGNEE to apply in all countries in my/our name(s) or in its own name for patents, utility models, design registrations, and like rights of exclusion and for inventors' certificates, for said invention(s) and improvement(s);

the same to be held and enjoyed by the ASSIGNEE for its own use and behalf and for the use and behalf of its successors, legal representatives and assigns, absolutely during the residue of the respective terms for which the United States and foreign patents will be granted, and for any and all


rights extending from said applications and reissues, and entirely as the same would have been held and enjoyed by me/us had this assignment not been made:

and I/We agree for me/us, and my/our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Declarations and other lawful documents as ASSIGNEE may reasonably request to effectuate fully the assignment.

INVENTOR 1:

 Date: 10/3/17  
John H. Balle

Witnessed by:


 Date: 10/3/2017  
Name: John H. Balle

AND by \_\_\_\_\_ Date: \_\_\_\_\_  
Name: \_\_\_\_\_

INVENTOR 2:

 Date: 10/3/17  
Ruth Shelle

Witnessed by:

 Date: 10/3/2017  
Name: Ruth Shelle


AND by \_\_\_\_\_ Date: 10/3/17  
Name: Ruth Shelle

INVENTOR 2:

  
George Brown

Date: 10/3/2017

Witnessed by:

  
Name: Steven Vogel

Date: 10/3/2017

AND by

\_\_\_\_\_  
Name: \_\_\_\_\_

Date: \_\_\_\_\_

INVENTOR 4:

  
Newsha Farhani

Date: 10/3/17

Witnessed by:

  
Name: Steven Vogel

Date: 10/3/2017

AND by

\_\_\_\_\_  
Name: \_\_\_\_\_

Date: \_\_\_\_\_

Attorney Docket No. 2034-02-011202  
U.S. Patent Application Ser. No. 15/780,521

ASSIGNMENT OF RIGHTS

INVENTOR S:

Christopher Mark  
Christopher Mark

Date: 10/03/2017

Witnessed by: [Signature]  
Name: [Signature]

Date: 10/3/2017

AND by: \_\_\_\_\_  
Name: \_\_\_\_\_

Date: \_\_\_\_\_